Clinical Trial Update: Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating MEM 3454 as an adjunct to an existing antipsychotic for cognitive impairment associated with schizophrenia; the current stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment Associated with Schizophrenia

Drugs mentioned

• MEM 3454

Snippet

Sponsor: Memory Pharmaceuticals | Conditions: Cognitive Impairment Associated With Schizophrenia | Phase 2 | Status: UNKNOWN